Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKIN.L Regulatory News (SKIN)

  • There is currently no data for SKIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

3 year $3.75m (£3.12m) bacteria prod'n agreement

18 Mar 2020 07:00

RNS Number : 5261G
Integumen PLC
18 March 2020
 

AIM share code: SKIN

18 March 2020

 

Integumen PLC

 

("Integumen" or "Company")

 

Integumen signs three year $3.75m (£3.12m) bacteria production agreement with Modern Water plc

 

Labskin Laboratories to expand 100% in Q2 2020 to meet increased demand

 

Integumen announces that it has signed a three-year revenue-sharing, manufacturing agency agreement ("Agreement") with Modern Water plc ("Modern Water") to manufacture and provide logistic support for the Modern Water's monitoring reagent consumables. The Agreement is for $1.25m (£1.04m) per year for 3-years, worth a total of $3.75m (£3.12m). The revenue share split is 60% / 40% in favour of Modern Water, after costs, and is subject to rolling 12-month extensions thereafter.

 

In addition, Integumen confirms a further 100% expansion of its purpose-built product and development laboratories in York, UK, to 6,000 square feet, adding six more laboratory rooms to meet growing demand. Two of those laboratories will be allocated to the production of Modern Water's bacteria reagent. As part of the Agreement, a further three full-time laboratory technicians will be recruited to join Integumen's team of highly skilled scientific specialists in bacteria, virus and toxins.

 

Gerard Brandon CEO Integumen plc commented:

"We are delighted to announce the continued expansion of our laboratories and to be able to provide European bacteria reagent manufacturing capacity and logistic support to Modern Water's sales, marketing and distribution in the US, EU, China and Japan. This Agreement demonstrates demand for Integumen's services and our capacity to maintain exponential growth regardless of the uncertainties of Brexit or the Coronavirus. In addition to production of the bacteria reagents, our AI division is exploring options to develop data analytic tools for Modern Water monitoring equipment, with the potential to add higher-value bolt-on real-time alert services leading to increased revenue per client."

 

Simon Humphrey CEO of Modern Water, commented:

"This Agreement is a water-shed moment for Modern Water. We are moving from a self-contained production, sales, marketing and distribution company to a collaborative, cooperation and partnership business model. This immediately gives Modern Water access to state-of-the art laboratories in the UK without the need for capital expenditure. Integumen's superior development and manufacturing capabilities will enable us to rapidly grow our existing network of sales, marketing and distribution channels, delivering the quality of product we are synonymous with, whilst lowering operational costs."

 

Integumen plc

Gerard Brandon, CEO

+44 (0) 7340 055 648

SPARK Advisory Partners Limited

(Nominated Adviser)

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/Zoe Alexander

+44 (0) 20 3657 0050

 

Notes:

Gerard Brandon is CEO, Executive Director and a shareholder of Integumen and is also Non-Executive Chairman and shareholder of Modern Water. Given this conflict of interest, Gerard is not regarded as independent and has taken no part in the Company's consideration or the decision to enter into the Agreement with Modern Water. Ross Andrews, Non-Executive Chairman, Fin Murray, Executive Director, and Camillus Glover, Executive Director, are regarded as independent and have evaluated and agreed the final terms of the Agreement.

 

About Integumen plc

Integumen is a scientific research and AI-as-a-Service company focused on production and analysis of bacteria, virus and toxins utilising artificial intelligent data analytics in regulatory technology, from scientifically proving the impact of skincare product claims on skin microbiome for top 10 global cosmetic company clients to remotely detecting water contamination in real-time.

 

About Modern Water

Modern Water was established in 2006 to develop and commercialise water recovery technologies to counter water crisis problems arising from climate change and a growing global population. Having invested £20m over the last 14 years, the results comprise of a robust patent portfolio in cutting-edge technology, focussed on monitoring of contaminated water and decontamination of wastewater, making recycling of water more efficient. Six countries across the world have legislated that Modern Water monitoring test systems are written into their environmental protection legislation.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRUBVNRRVUOAAR
Date   Source Headline
28th Apr 20204:37 pmRNSPrice Monitoring Extension
28th Apr 20202:05 pmRNSSecond Price Monitoring Extn
28th Apr 20202:00 pmRNSPrice Monitoring Extension
17th Apr 20202:06 pmRNSSecond Price Monitoring Extn
17th Apr 20202:00 pmRNSPrice Monitoring Extension
30th Mar 20207:00 amRNSUpdate re COVID 19; confirmed orders; investment
23rd Mar 20207:00 amRNSDirector/PDMR Shareholding
18th Mar 202010:22 amRNSDirector/PDMR Shareholding
18th Mar 20207:00 amRNS3 year $3.75m (£3.12m) bacteria prod'n agreement
12th Mar 20202:06 pmRNSSecond Price Monitoring Extn
12th Mar 20202:00 pmRNSPrice Monitoring Extension
26th Feb 20207:00 amRNSLaunch of ecowaterOS; Company Update
7th Feb 20207:00 amRNSIntegumen plc to present at The UK Investor Show
3rd Feb 20207:00 amRNSCommercial & AI partnership with Acumen Software
21st Jan 20207:00 amRNSCooperative Alliance; Trading Update
19th Dec 20197:00 amRNS3-year Rev sharing Framework Ag with Parity Group
16th Dec 20198:43 amRNSDirector/PDMR Shareholdings
9th Dec 201911:05 amRNSPlacing/Subscription to raise £1.368m -replacement
9th Dec 20197:00 amRNSPlacing and subscription to raise £1.368 million
20th Nov 20197:00 amRNSResults of AI water research project
13th Nov 20197:00 amRNSHeads of Terms -Framework Agreement;trading update
7th Nov 20197:00 amRNSMicrobiome and Labskin clone R&D agreements signed
29th Oct 20197:00 amRNSLaunch of ind. Rinodrive AI open-source eco-system
21st Oct 20197:00 amRNSRinocloud subsidiary wins "One To Watch" IT award
8th Oct 201912:34 pmRNSIssue of Equity: Shares in Lieu of Invoice
7th Oct 20197:00 amRNSLabskin signs multi-year service agreement
7th Oct 20197:00 amRNSLabskinAI creates virtual AI psoriasis skin model
11th Sep 20197:00 amRNSInterim Results
5th Sep 20197:00 amRNSLabskin breakthrough clones 16 human skin swabs
2nd Aug 20197:00 amRNSHighlands Nat. Resources agreement with Cellulac
1st Aug 20191:41 pmRNSExercise of Warrants
1st Aug 201911:32 amRNSExercise of Warrants
31st Jul 20194:30 pmRNSResult of AGM
31st Jul 20197:00 amRNSAGM - Trading Update
29th Jul 20197:00 amRNSCollaboration; Expansion of wound care division
19th Jul 20197:00 amRNSLabskinAI:agreementswith global cosmetic companies
12th Jul 20197:00 amRNSChange to interests of a significant shareholder
11th Jul 201910:38 amRNSExercise of Warrants (update)
10th Jul 201912:55 pmRNSExercise of warrants
8th Jul 20197:00 amRNSAGM Notice and Trading Update
28th Jun 20193:03 pmRNSExercise of Warrants
27th Jun 20197:00 amRNSFinal Results
21st Jun 20197:00 amRNSExercise of Warrants
20th Jun 20197:01 amRNSExecutive team and Labskin AI digital hub updates
20th Jun 20197:00 amRNSExercise of Warrants
10th Jun 20197:00 amRNSExercise of Warrant Shares and Call Option Shares
28th May 20197:30 amRNSExercise of Warrants
28th May 20197:00 amRNSNew Labskin AI contracts; additional lab space
21st May 20197:00 amRNSTrading update and Board changes
10th May 201912:19 pmRNSLaunch of Labskin human skin clone tests

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.